Alessandro Sciarra1, Martina Maggi2, Stefano Salciccia1, Alice Nicolai3, Elisabetta Tortorella4, Sabrina Giantulli4, Fabio Massimo Magliocca5, Ida Silvestri4, Ludovica Taglieri3, Susanna Cattarino1, Susanna Scarpa3. 1. Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy. 2. Department of Urology, Sapienza Rome University, Policlinico Umberto I, Rome, Italy, martina.maggi@uniroma1.it. 3. Department of Experimental Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy. 4. Department of Molecular Medicine, Sapienza Rome University, Policlinico Umberto I, Rome, Italy. 5. Department of Radiological, Oncological and Anatomopathological Sciences, Sapienza Rome University, Policlinico Umberto I, Rome, Italy.
Abstract
BACKGROUND: Androgen receptor splice variant V7 (AR-V7) was recently detected in circulating tumor cells of castration-resistant prostate cancer (PC) patients and its expression correlated with resistance to new-generation androgen signaling inhibitors. OBJECTIVES: We retrospectively analyzed whether AR-V7 expression was detectable on radical prostatectomy (RP) specimens of untreated nonmetastatic PC cases, and whether it could be associated with progression after surgery. METHOD: The expression of AR-V7 and AR-FL (full length) was separately evaluated by immunohistochemistry using a streptavidin-biotin-peroxidase system with 2 anti-AR-V7 and anti-AR-FL rabbit monoclonal antibodies. RESULTS: 56 PC cases, classified by their clinical risk, were analyzed. Positive expression was found in 24/32 cases in the high-risk group, 4/13 in the intermediate-risk group, and only 2/11 in the low-risk group. We found a significant correlation between AR-V7 positivity and both risk classification (p < 0.001) and progression after surgery (p < 0.001). CONCLUSIONS: In our population of untreated nonmetastatic PC, AR-V7 is detectable by immunohistochemistry in more than 50% of cases. At this early stage, AR-V7 positivity is associated with risk classification and it can predict progression after surgery.
BACKGROUND:Androgen receptor splice variant V7 (AR-V7) was recently detected in circulating tumor cells of castration-resistant prostate cancer (PC) patients and its expression correlated with resistance to new-generation androgen signaling inhibitors. OBJECTIVES: We retrospectively analyzed whether AR-V7 expression was detectable on radical prostatectomy (RP) specimens of untreated nonmetastatic PC cases, and whether it could be associated with progression after surgery. METHOD: The expression of AR-V7 and AR-FL (full length) was separately evaluated by immunohistochemistry using a streptavidin-biotin-peroxidase system with 2 anti-AR-V7 and anti-AR-FL rabbit monoclonal antibodies. RESULTS: 56 PC cases, classified by their clinical risk, were analyzed. Positive expression was found in 24/32 cases in the high-risk group, 4/13 in the intermediate-risk group, and only 2/11 in the low-risk group. We found a significant correlation between AR-V7 positivity and both risk classification (p < 0.001) and progression after surgery (p < 0.001). CONCLUSIONS: In our population of untreated nonmetastatic PC, AR-V7 is detectable by immunohistochemistry in more than 50% of cases. At this early stage, AR-V7 positivity is associated with risk classification and it can predict progression after surgery.
Authors: Stefano Salciccia; Davide Rosati; Pietro Viscuso; Vittorio Canale; Emiliano Scarrone; Marco Frisenda; Roberta Catuzzi; Martina Moriconi; Vincenzo Asero; Stefano Signore; Mauro De Dominicis; Paolo Emiliozzi; Antonio Carbone; Antonio Luigi Pastore; Andrea Fuschi; Giovanni Battista Di Pierro; Alessandro Gentilucci; Susanna Cattarino; Gianna Mariotti; Gian Maria Busetto; Matteo Ferro; Ettore De Berardinis; Gian Piero Ricciuti; Valeria Panebianco; Fabio Massimo Magliocca; Francesco Del Giudice; Martina Maggi; Alessandro Sciarra Journal: Cent European J Urol Date: 2021-11-29
Authors: Isabel Quiros-Gonzalez; Pedro Gonzalez-Menendez; Juan C Mayo; David Hevia; Francisco Artime-Naveda; Sheila Fernandez-Vega; Mario Fernandez-Fernandez; Pablo Rodriguez-Gonzalez; José I Garcia-Alonso; Rosa M Sainz Journal: Antioxidants (Basel) Date: 2022-02-04
Authors: Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru Journal: Ther Adv Urol Date: 2022-07-04